Dual Path Platform
(DPP™)
The Dual Path Platform (DPP™) Technology (US Patent# 7,189,522) was developed as a platform for next generation, rapid diagnostic testing. Chembio believes that this technology allows the freedom to operate in the POC sector and offers a novel, low-cost, rapid technology as an alternative to established Single Path Lateral Flow formats. Advantages of DPP include increased analytical and clinical sensitivity, multiplexing capabilities and quantifiable results. The technology is available for application in diverse global diagnostic markets for human and veterinary assays, food safety, bioterrorism, environmental testing, etc. The company is seeking license opportunities outside of its core business focus.
DPP Features:
- Increased analytical and clinical sensitivity*
- Outside the standard lateral flow IP
- Less labor intensive than EIA, PCR or WB
- Potential ideal confirmatory test
- Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc.
- Multiplex capability through elimination of aggregation issues (ie HIV/TB, HIV 1/ 2, etc.)
- Ideally suited for POC testing
- Requires minimal sample volume
- Long shelf life (up to 24 months)
- Total test time < 20 minutes
Diverse Potential Applications include:
- Medical Diagnostics
- Consumer & OTC Products
- Veterinary Diagnostics
- Food Safety
- Environmental Screening
- Bioterriosm
- Forensics
- Agricultural & Industrial Applications
*Internal Chembio study data on HIV, TB and Leptospirosis.
